TD Cowen analyst Steve Scala raised the firm’s price target on Merck (MRK) to $120 from $100 and keeps a Hold rating on the shares. The firm said Merck is a great company, but barring bolstering of growth outlook, they think it is unlikely to be a top pharma stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Modern, Merck announce 5-year data for intismeran autogene with Keytruda
- Merck: Solid Near-Term Earnings but Muted Post-LOE Growth Keeps Rating at Hold
- Guardant Health announces multi-year strategic agreement with Merck
- Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- Midday Fly By: PNC reports Q4 beat, Regions reports quarterly miss